Inspira Technologies OXY B.H.N. Ltd - Annual Performance Review

I’ve put together this guide to help you understand Inspira Technologies’ latest annual report. I’ve broken down the key points so you can see exactly how the company is performing without the confusing financial jargon.

1. What does this company do?

Inspira Technologies is an Israeli medical device company changing how we treat severe breathing problems. Currently, doctors often use mechanical ventilation, which requires putting patients into a medically induced coma and using invasive tubes. Inspira is developing technology to oxygenate blood without the coma, aiming for faster recoveries and fewer complications. They operate in the global respiratory care market, which is expected to grow as the population ages.

2. Major wins this year

The company is successfully moving from "concept" to "real-world product":

• Regulatory Milestones: In May 2024, their INSPIRA ART100 system received FDA clearance. By July 2024, they also received approval from the Israeli Ministry of Health. These approvals confirm the device is safe for use in hospitals.
• First Deployment: In December 2024, they began shipping the ART100 to Westchester Medical Center in New York for real-world testing. This is a critical step in moving the company from research to a commercial business.

3. Their "Flagship" Products

• INSPIRA ART100: This is their currently approved system. It helps during surgeries lasting up to six hours by temporarily taking over heart or lung functions. It is the company's entry point into hospitals.
• INSPIRA ART500: This is their "big bet" for the ICU. It is designed to oxygenate blood in real-time for patients who are awake. It aims to replace invasive mechanical ventilation.
• HYLA Blood Sensor: This new technology monitors blood in real-time without needing to draw blood. They plan to sell this as a standalone product or as part of their ART systems, which could create steady, recurring sales.

4. Financial Health: The "Going Concern" Warning

This is the most important part for an investor: Inspira is in a high-risk phase.

• No Significant Sales: As of December 31, 2023, the company had almost no revenue because the ART100 was still awaiting approval.
• "Going Concern" Status: Auditors have flagged a "going concern" warning. This means there is doubt about whether the company has enough cash to operate for the next 12 months without raising more money.
• Cash Needs: The company has about $6.5 million in cash. With annual losses over $15 million, they are burning through money quickly. They will need to raise more capital soon, which will likely mean issuing more shares and reducing your ownership percentage.

5. What to watch for (Risks)

• Funding: Because they aren't profitable, their survival depends on raising more money. This is difficult and depends on their stock performance.
• Competition: They are competing against massive, well-funded companies like Medtronic and Getinge.
• Execution: If they cannot get hospitals to buy their products, their business model will fail.
• Regulatory Risk: While the ART100 is approved, the ART500 and HYLA sensor still need expensive, uncertain clinical trials.

6. Future Outlook

Inspira is shifting from a research lab to a commercial company. The focus is now on proving the ART100 in hospitals and developing the ART500 and HYLA sensor. If they secure partnerships and prove their tech works, they have a path to growth. Until they generate consistent profit, this remains a high-risk investment.

Investor Checklist:

• Monitor Cash Levels: Keep an eye on their quarterly cash burn and any announcements regarding new stock offerings.
• Track Hospital Adoption: Look for news regarding additional hospital contracts beyond Westchester Medical Center.
• Watch for Clinical Updates: Any progress on the ART500 or HYLA sensor trials is a major indicator of future value.